| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 24 | 2023 | 1402 | 1.860 |
Why?
|
| Tissue Array Analysis | 6 | 2010 | 135 | 0.690 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2017 | 100 | 0.610 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 99 | 0.600 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 741 | 0.580 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 258 | 0.530 |
Why?
|
| Prostatectomy | 7 | 2016 | 301 | 0.520 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2007 | 995 | 0.480 |
Why?
|
| Nephrectomy | 1 | 2017 | 155 | 0.470 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 68 | 0.470 |
Why?
|
| Radiotherapy | 1 | 2016 | 120 | 0.460 |
Why?
|
| Mesothelioma | 1 | 2017 | 95 | 0.460 |
Why?
|
| Pneumonectomy | 1 | 2017 | 153 | 0.460 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 222 | 0.440 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 151 | 0.440 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 419 | 0.380 |
Why?
|
| Biomarkers, Tumor | 7 | 2010 | 1583 | 0.370 |
Why?
|
| Gene Expression Profiling | 4 | 2012 | 1807 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1264 | 0.350 |
Why?
|
| Trans-Activators | 3 | 2008 | 700 | 0.330 |
Why?
|
| Prostate | 4 | 2023 | 400 | 0.290 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2007 | 237 | 0.280 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 103 | 0.280 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 1046 | 0.250 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1539 | 0.250 |
Why?
|
| Translocation, Genetic | 1 | 2007 | 343 | 0.230 |
Why?
|
| Radiosurgery | 2 | 2017 | 147 | 0.230 |
Why?
|
| Exons | 1 | 2007 | 761 | 0.220 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2005 | 38 | 0.220 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 964 | 0.220 |
Why?
|
| Aged | 18 | 2023 | 20837 | 0.210 |
Why?
|
| Prognosis | 9 | 2021 | 4852 | 0.210 |
Why?
|
| Immunohistochemistry | 7 | 2010 | 1594 | 0.210 |
Why?
|
| Male | 31 | 2023 | 64344 | 0.210 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2004 | 9 | 0.210 |
Why?
|
| Middle Aged | 19 | 2023 | 28334 | 0.200 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 59 | 0.200 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2023 | 7 | 0.200 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 147 | 0.190 |
Why?
|
| Lasers, Solid-State | 1 | 2023 | 23 | 0.190 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2023 | 39 | 0.190 |
Why?
|
| Prostatic Hyperplasia | 1 | 2023 | 108 | 0.180 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2010 | 58 | 0.180 |
Why?
|
| Biopsy, Needle | 5 | 2010 | 204 | 0.180 |
Why?
|
| Humans | 38 | 2023 | 130241 | 0.170 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2021 | 19 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2012 | 3396 | 0.170 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 35 | 0.170 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 44 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2023 | 241 | 0.160 |
Why?
|
| Transcriptional Regulator ERG | 3 | 2008 | 39 | 0.160 |
Why?
|
| Prostate-Specific Antigen | 4 | 2023 | 221 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 486 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2004 | 630 | 0.140 |
Why?
|
| Space Flight | 1 | 2021 | 176 | 0.130 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2016 | 6 | 0.120 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 78 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 6780 | 0.120 |
Why?
|
| DNA-Binding Proteins | 3 | 2008 | 1946 | 0.120 |
Why?
|
| Adult | 12 | 2017 | 31092 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2021 | 1074 | 0.100 |
Why?
|
| Burkitt Lymphoma | 2 | 2012 | 130 | 0.100 |
Why?
|
| Prostatic Secretory Proteins | 2 | 2010 | 3 | 0.100 |
Why?
|
| Aging | 1 | 2021 | 1241 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 349 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2017 | 375 | 0.100 |
Why?
|
| Reoperation | 1 | 2016 | 818 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2021 | 6435 | 0.100 |
Why?
|
| Guanylate Cyclase | 1 | 2012 | 33 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2009 | 743 | 0.090 |
Why?
|
| Lymphocytosis | 1 | 2012 | 15 | 0.090 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2012 | 43 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 1279 | 0.090 |
Why?
|
| Germ-Line Mutation | 2 | 2012 | 372 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2010 | 2010 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2007 | 2553 | 0.090 |
Why?
|
| Risk Factors | 5 | 2017 | 10937 | 0.080 |
Why?
|
| Genes, BRCA2 | 1 | 2010 | 48 | 0.080 |
Why?
|
| Genotype | 5 | 2010 | 2590 | 0.080 |
Why?
|
| BRCA2 Protein | 1 | 2010 | 56 | 0.080 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2010 | 93 | 0.080 |
Why?
|
| Oncogenes | 1 | 2010 | 163 | 0.080 |
Why?
|
| BRCA1 Protein | 1 | 2010 | 79 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 382 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 510 | 0.080 |
Why?
|
| Lung | 1 | 2017 | 1531 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 77 | 0.080 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 2596 | 0.070 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2008 | 4 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12827 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2008 | 6 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 152 | 0.070 |
Why?
|
| Racemases and Epimerases | 1 | 2008 | 12 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 49 | 0.070 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2007 | 41 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2007 | 80 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2007 | 58 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2008 | 2423 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2008 | 171 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 227 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3745 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2008 | 307 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 723 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 422 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2007 | 591 | 0.060 |
Why?
|
| Alleles | 1 | 2010 | 1677 | 0.060 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2006 | 49 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1206 | 0.060 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 63 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 574 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 899 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 280 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2010 | 3358 | 0.050 |
Why?
|
| Mutation | 4 | 2010 | 6085 | 0.050 |
Why?
|
| Female | 5 | 2021 | 70257 | 0.050 |
Why?
|
| Genomics | 1 | 2012 | 1612 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2008 | 1590 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 126 | 0.050 |
Why?
|
| Tobacco, Smokeless | 1 | 2004 | 10 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2017 | 17497 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2008 | 998 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 2822 | 0.050 |
Why?
|
| Holmium | 1 | 2023 | 9 | 0.050 |
Why?
|
| India | 1 | 2004 | 245 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 741 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2017 | 107 | 0.050 |
Why?
|
| Young Adult | 1 | 2017 | 9990 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 356 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2012 | 887 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 103 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 1218 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2004 | 759 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2008 | 5046 | 0.050 |
Why?
|
| Disease Progression | 1 | 2008 | 2194 | 0.040 |
Why?
|
| RNA | 1 | 2005 | 513 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 562 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2017 | 14933 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 79 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 1455 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2001 | 217 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2001 | 331 | 0.040 |
Why?
|
| Formaldehyde | 2 | 2010 | 50 | 0.040 |
Why?
|
| RNA Interference | 2 | 2012 | 493 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 785 | 0.040 |
Why?
|
| Telomere | 1 | 2021 | 217 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2006 | 1541 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2012 | 441 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2005 | 561 | 0.040 |
Why?
|
| Adolescent | 1 | 2017 | 20706 | 0.040 |
Why?
|
| Smoking | 1 | 2004 | 928 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 3473 | 0.030 |
Why?
|
| Cancer Pain | 1 | 2017 | 25 | 0.030 |
Why?
|
| Narcotics | 1 | 2017 | 59 | 0.030 |
Why?
|
| Craniotomy | 1 | 2017 | 102 | 0.030 |
Why?
|
| Child | 1 | 2017 | 26071 | 0.030 |
Why?
|
| Spine | 1 | 2017 | 151 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2010 | 1481 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5163 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1241 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2012 | 4672 | 0.020 |
Why?
|
| Palliative Care | 1 | 2017 | 443 | 0.020 |
Why?
|
| Cyclin D3 | 1 | 2012 | 11 | 0.020 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2012 | 11 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2012 | 32 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2012 | 31 | 0.020 |
Why?
|
| Genes, myc | 1 | 2012 | 95 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 291 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 49 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 412 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 339 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2010 | 25 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 21 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2010 | 65 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 61 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2010 | 35 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2010 | 38 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 336 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 83 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 112 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 3705 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2010 | 18 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 766 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 123 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 597 | 0.020 |
Why?
|
| Fixatives | 1 | 2009 | 15 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 404 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2009 | 40 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 159 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 142 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2060 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 715 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2009 | 45 | 0.020 |
Why?
|
| Microdissection | 1 | 2008 | 13 | 0.020 |
Why?
|
| Kallikreins | 1 | 2008 | 26 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 1672 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2010 | 228 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2737 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 829 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 368 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Echo-Planar Imaging | 1 | 2008 | 21 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 679 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 413 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 278 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 922 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 85 | 0.020 |
Why?
|
| Osteopontin | 1 | 2008 | 54 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2010 | 410 | 0.020 |
Why?
|
| Australia | 1 | 2008 | 171 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 306 | 0.020 |
Why?
|
| United Kingdom | 1 | 2008 | 257 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 230 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1573 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2400 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 959 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 677 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2007 | 195 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 1017 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 665 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 331 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 1073 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 479 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 2 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2006 | 207 | 0.010 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2005 | 7 | 0.010 |
Why?
|
| E2F3 Transcription Factor | 1 | 2004 | 11 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 1341 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 1389 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 902 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 425 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 1486 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2004 | 220 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 2088 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 1268 | 0.010 |
Why?
|
| Genome, Human | 1 | 2009 | 1313 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 511 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1822 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 1098 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 1660 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 3665 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 4465 | 0.010 |
Why?
|